Boston, MA -- (SBWIRE) -- 11/27/2015 -- Our outlook for Kenya's pharmac eutical expenditure is positive and will be driven by expanding national health insurance coverage and improving public healthcare provision. While the Kenyan government is focused on improving its population's access to healthcare, drugmakers and medical device companies looking for a rapid return on investment will face challenges. Poor healthcare human resources and infrastructure will continue to limit the population ' s access to healthcare.

Headline Expenditure Projections

Pharmaceuticals: KES63.75bn (USD725mn) in 2014 to KES73.37bn (USD768mn) in 2015; 15.1% growth in local currency terms and 5.9% in US dollar terms.
Healthcare: KES190.34bn (USD2.16bn) in 2014 to KES212.93bn (USD2.23bn) in 2015; 11.8% growth in local currency terms and 2.9% in US dollar terms.

Risk/Reward Index

In BMI's Q415 Pharmaceutical and Healthcare Risk/Reward Index, Kenya is 19th in the Middle East and Africa (MEA) region. A large counterfeit drug industry, poor healthcare funding, corruption, regulatory deficiencies and a number of other issues will conspire to keep Kenya in a low position in the MEA matrix. Nevertheless, in comparison with many other African markets, most of which are not surveyed by BMI, Kenya offers greater commercial promise and a more stable overall business environment.

Get More Details on this Report and a Full Table of Contents at Kenya Pharmaceuticals & Healthcare Report Q1 2016

Key Trends And Developments

In July 2015, Swiss drugmaker Novartis announced a collaboration with Strathmore University in Kenya on the Community Health Educator Replication (CHER) programme to train healthcare workers in the country.

In June 2015, it was announced that the cost of medicines in Kenya is set to fall as the result of a number of non-profit organisations teaming up to jointly procure medicines, benefiting from economies of scale.

The Kenya Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kenya Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kenya pharmaceutical and healthcare industry.

Key Benefits

-Benchmark BMI's pharmaceutical and healthcare market forecasts for Kenya, to test other views - a key input for successful budgeting and strategic business planning in the Kenyan pharmaceutical and healthcare market.
-Target business opportunities and risks in the Kenyan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kenya.
-Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI?s forecast analysis, and taken together with BMI?s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

-Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ?000 population).
-Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
-Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
-Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
-OTC Drug Market: OTC sales (USDbn & % of total sales).
-Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI?s Pharmaceuticals and Healthcare Risk Reward Index

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

-Thailand Pharmaceuticals & Healthcare Report Q1 2016
-Pakistan Pharmaceuticals & Healthcare Report Q1 2016
-Argentina Pharmaceuticals & Healthcare Report Q1 2016
-Croatia Pharmaceuticals & Healthcare Report Q1 2016
-Puerto Rico Pharmaceuticals & Healthcare Report Q1 2016